This Week in Pulmonary — Aug 25, 2026

Welcome to This Week in Pulmonary. This week we're covering 10 notable papers spanning biologics and exacerbation biology in COPD, health system inequalities and continuity of care, and new imaging and oncology data across cystic fibrosis and lung cancer. Let's dive in.

We start with COPD and the type 2 inflammation story, where Chest published a matching-adjusted indirect comparison from Bourbeau and colleagues asking a question every clinician now faces: mepolizumab or dupilumab for the patient with eosinophilic COPD [1]. There is no head to head trial, so the authors pooled individual patient data from the three mepolizumab trials, METREX, METREO and MATINEE, reweighted those patients to match the baseline characteristics of the dupilumab BOREAS and NOTUS populations, and restricted to the narrower dupilumab eligibility, meaning eosinophils at or above 300 cells per microlitre, significant breathlessness, and chronic bronchitis. Across both definitions of chronic bronchitis there was no statistically significant difference between the two agents in the annualised rate of moderate or severe exacerbations, and no significant difference in quality of life measured by the St George's questionnaire. This is indirect evidence with all the usual caveats about unmeasured differences between trial populations, but the practical message is that choice between these two biologics can reasonably rest on comorbid type 2 disease, dosing, access and cost, rather than on a presumed efficacy gap.

Staying with COPD, Respiratory Medicine published a paper that pushes back on how we triage exacerbations by severity. Zhou and colleagues followed just over 700 patients from the Early COPD cohort in China with complete annual spirometry over three years [3]. Patients who had any exacerbation, including mild events treated only at home, lost lung function faster than those with none, with an adjusted difference of about 13 millilitres per year in post bronchodilator forced expiratory volume in one second. Crucially the direction of effect held in mild to moderate disease and in the GOLD A group, the very patients we tend to reassure. If confirmed, this argues that a home treated flare is not a benign event and belongs in the risk conversation. Two other COPD papers add prognostic texture. In the International Journal of COPD, Ko and colleagues analysed nearly thirty thousand newly diagnosed older adults in the Korean national insurance cohort and found that fragmented outpatient care, measured by low continuity of care indices, was associated with roughly a sixty percent higher risk of exacerbation related hospitalisation over three years and about a quarter higher all cause mortality [8]. The finding was consistent across four different continuity indices, which is reassuring, though residual confounding by illness severity is hard to exclude. And in the same journal, Xie and colleagues used the MIMIC-IV intensive care database to show that in critically ill patients with both COPD and atrial fibrillation, a higher red cell distribution width at admission tracked with in hospital, twenty eight day, ninety day and one year mortality in a graded fashion, with the top quartile carrying roughly two and a half times the odds of dying in hospital compared with the lowest [9]. That is a free number already on your complete blood count, but it is an adjunctive risk marker, not an action item.

The second theme is who bears the burden of chronic respiratory disease, and Thorax published a large population study that should sober anyone who assumes inequalities are narrowing. Whittaker and colleagues linked English primary care records for more than seven and a half million people with asthma and over a million with COPD to hospital and mortality data from November 2019 through March 2025 [6]. Exacerbation rates were about a third higher in women than men for both conditions, while all cause mortality ran higher in men. The deprivation gradient was the striking finding: people in the most deprived decile had roughly double the exacerbation rate and double the mortality in asthma compared with the least deprived, and in COPD around two thirds higher exacerbations and about forty percent higher mortality. Regional gaps between the northeast and southwest persisted, and outcomes varied by ethnicity. Despite years of policy attention, these gaps have not closed, which matters when we design follow up pathways and decide where to concentrate case finding.

Turning to imaging and risk stratification, Chest published a Korean screening cohort from Nam and colleagues covering more than forty one thousand adults who had chest CT as part of routine health checkups [7]. Emphysema was reported in about nine percent of participants, rising from under three percent in never smokers to nearly fifteen percent in current smokers. Among ever smokers, incidental emphysema was associated with roughly a sixty percent higher risk of death even after adjusting for pack years. But the authors are admirably restrained: adding emphysema to a model that already includes smoking improved discrimination by essentially nothing, and in the full cohort the association did not reach statistical significance, a result they call inconclusive rather than negative given only 284 deaths. The practical reading is that an incidental emphysema line on a screening report should not by itself drive prognostic counselling once you know the smoking history, though whether it should trigger evaluation for undiagnosed COPD remains open. Two cystic fibrosis papers round out the imaging theme. In Thorax, Dhote and colleagues studied nearly three hundred adults with cystic fibrosis before and twelve months after starting elexacaftor-tezacaftor-ivacaftor [4]. Before treatment, about three quarters of patients had static hyperinflation defined by an elevated residual volume to total lung capacity ratio. After a year of modulator therapy that ratio fell by a median of about five percentage points, yet it remained abnormal in sixty five percent of patients, including some whose spirometry had normalised. Normal forced expiratory volume in one second on modulators does not mean normal lung mechanics, and plethysmography may deserve a place in follow up. Complementing that, Respiratory Medicine reported a single centre descriptive study by Giraudi and colleagues of lung ultrasound in thirty five children with cystic fibrosis using a standardised twelve zone score [10]. Abnormalities, mostly B lines and small subpleural consolidations, were seen in about two thirds of children, the score correlated strongly and inversely with percent predicted lung function and with body mass index, children on modulator therapy had lower scores, and ultrasound picked up abnormalities in just over a quarter of examinations where the chest radiograph looked normal. Computed tomography remained superior for proximal lesions, so this is a complementary radiation free monitoring tool, not a replacement, and the sample is small.

Finally, two thoracic oncology papers. In the Journal of Thoracic Oncology, Wu and colleagues report a multicentre single arm phase two b trial of sutetinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor, in 99 treatment naive patients with advanced non small cell lung cancer carrying uncommon mutations such as G719X, S768I and L861Q [2]. The independently confirmed objective response rate was about seventy one percent, disease control about ninety one percent, and median progression free survival was 13.7 months, with responses numerically better in compound mutations. Toxicity was real, with grade three or higher treatment related events in just over forty percent, driven largely by diarrhoea, and a third of patients needing dose reduction, though discontinuation was uncommon and there were no treatment related deaths. This is single arm data, but it is meaningful prospective evidence in a group historically served by extrapolation. Separately, Thorax published a multi institutional cohort from Atkins and colleagues of 848 patients receiving thoracic radiotherapy for non small cell lung cancer [5]. The two year cumulative incidence of pulmonary hypertension was nearly twelve percent, and the dose delivered to the pulmonary arteries, specifically the volume receiving ten gray, was the strongest predictor, replicating in a validation cohort. Patients who developed pulmonary hypertension were far more likely to have tricuspid disease and right ventricular systolic dysfunction. Discrimination was modest and the findings are hypothesis generating, but they suggest a vascular mechanism distinct from radiation fibrosis and a possible new organ at risk for treatment planning.

If you only have time for one paper this week, make it the mepolizumab versus dupilumab comparison in Chest [1]. It addresses a decision that is landing in clinics right now, and the absence of a demonstrated efficacy difference reframes biologic selection in eosinophilic COPD around access, comorbidity and patient preference.

Here are the key takeaways from this week in Pulmonary. First, indirect comparison shows no significant efficacy separation between mepolizumab and dupilumab in eosinophilic COPD, so choose on practical grounds. Second, even mild home treated exacerbations track with faster lung function decline, including in GOLD A patients, so stop treating them as trivial. Third, fragmented outpatient care is associated with substantially more COPD hospitalisation and death, and inequalities by deprivation, sex, region and ethnicity in England remain wide. Fourth, incidental emphysema on a screening CT adds almost nothing prognostically once you know the smoking history. And fifth, in cystic fibrosis, hyperinflation persists in most adults despite highly effective modulator therapy, while lung ultrasound offers a radiation free adjunct in children that outperforms plain radiography.

That's your roundup for This Week in Pulmonary. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And think of one colleague — in any specialty — who never has time to keep up with the literature. Tell them about AudioScholar: a free ten-minute weekly for every specialty, to listen to in any podcast app, or to read at audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.